3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Epoetin Alfa
3
Darbepoetin alfa
3
cobomarsen
2
Therapeutics
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Early Intervention, Educational
2
Antilymphocyte Serum
2
vandetanib
1
tirbanibulin
1
sargramostim
1
motesanib diphosphate
1
imetelstat
1
fludarabine phosphate
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
ethanolamine oleate
1
entrectinib
1
atezolizumab
1
Vorinostat
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Thiotepa
1
Sulfamethoxazole
1
Sucrose
1
Sodium Chloride
1
Sirolimus
1
Saline Solution, Hypertonic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
cobomarsen
×
Dermatologic
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled